Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tobramycin dry-powder inhalation - Novartis

Drug Profile

Tobramycin dry-powder inhalation - Novartis

Alternative Names: TBM 100; TIP; TOBI Podhaler; TOBI-TIP; Tobramycin inhalation powder-Novartis

Latest Information Update: 26 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer Novartis
  • Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • No development reported Bronchiectasis

Most Recent Events

  • 26 Apr 2022 No development reported - Phase-II for Bronchiectasis (Adjunctive treatment, Non-cystic fibrosis-related) in Italy, Spain, Germany, Ireland, United Kingdom, Belgium, France, Netherlands (Inhalation)
  • 15 May 2020 Efficacy and adverse events data from a phase II iBest-1 trial in Bronchiectasis presented at the 116th International Conference of the American Thoracic Society (ATS-2020)
  • 20 Mar 2019 Novartis completes a phase II trial in Bronchiectasis (Adjunctive treatment, Non-cystic fibrosis related) in Italy, Spain, Germany, Ireland, United Kingdom, Belgium, Netherlands, France (Inhalation) (NCT02712983) (EudraCT2015-003040-39)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top